Actively Recruiting
A Study of ZL-1310 in Participants With Selected Solid Tumors
Led by Zai Lab (Shanghai) Co., Ltd. · Updated on 2026-05-08
112
Participants Needed
21
Research Sites
133 weeks
Total Duration
On this page
Sponsors
Z
Zai Lab (Shanghai) Co., Ltd.
Lead Sponsor
Z
Zai Lab (US) LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
CONDITIONS
Official Title
A Study of ZL-1310 in Participants With Selected Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Adult men and women 18 years of age or older
- Histologically confirmed, locally advanced or metastatic NeuroEndocrine Carcinomas (NEC) with disease progression on or after platinum-based therapy
- Willingness to undergo a tumor biopsy or provide archived tumor tissue sample
- At least one measurable target lesion as defined by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of 3 months or longer
You will not qualify if you...
- Another known malignancy that is progressing or requires active treatment within the last 2 years
- Clinically active central nervous system (CNS) metastases
- Presence of leptomeningeal metastasis
- Prior treatment with any antibody-drug conjugate (ADC) containing a topoisomerase I inhibitor payload (e.g., exatecan derivative)
- Systemic anti-cancer treatment or investigational products/devices within 3 weeks before first dose
- Non-palliative radiotherapy within 2 weeks to non-thoracic area or within 4 weeks to thoracic area before first dose, or history of radiation pneumonitis
- Major surgery within 4 weeks before first dose
- Hypersensitivity to any ingredient of the study treatment
- Out of range laboratory values as defined in protocol within 10 days prior to first dose
- Impaired cardiac function or clinically significant cardiac disease within 3 months before first dose
- Lung-specific intercurrent illnesses or autoimmune, connective tissue, or inflammatory disorders including pneumonitis
- History of noninfectious interstitial lung disease (ILD)/pneumonitis requiring steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis not ruled out by imaging at screening
- Pregnant or nursing (lactating) women
- Use of strong CYP3A or CYP2D6 inhibitors within 14 days or 5 half-lives before first dose, whichever is longer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
Zai Lab Site 2001
San Francisco, California, United States, 94143
Actively Recruiting
2
Zai Lab Site 2015
Peoria, Illinois, United States, 61637
Actively Recruiting
3
Zai Lab Site 2013
Detroit, Michigan, United States, 48201
Actively Recruiting
4
Zai Lab Site 2002
New York, New York, United States, 10065
Actively Recruiting
5
Zai Lab Site 2024
Cleveland, Ohio, United States, 44106
Actively Recruiting
6
Zai Lab Site 2004
Philadelphia, Pennsylvania, United States, 19111
Actively Recruiting
7
Zai Lab Site 2014
Nashville, Tennessee, United States, 37203
Actively Recruiting
8
Zai Lab Site 2003
Dallas, Texas, United States, 75246
Actively Recruiting
9
Zai Lab Site 2007
Houston, Texas, United States, 77030
Actively Recruiting
10
Zai Lab Site 2011
McAllen, Texas, United States, 78503
Actively Recruiting
11
Zai Lab Site 2006
Fairfax, Virginia, United States, 22031
Actively Recruiting
12
Zai Lab Site 2012
Norfolk, Virginia, United States, 23502
Actively Recruiting
13
Zai Lab Site 1002
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
14
Zai Lab Site 1013
Beijing, Beijing Municipality, China, 102200
Actively Recruiting
15
Zai Lab Site 1009
Xiamen, Fujian, China, 361003
Actively Recruiting
16
Zai Lab Site 1016
Guangzhou, Guangdong, China, 510030
Actively Recruiting
17
Zai Lab Site 1004
Guangzhou, Guangdong, China, 510080
Actively Recruiting
18
Zai Lab Site 1012
Harbin, Heilongjiang, China, 150081
Actively Recruiting
19
Zai Lab Site 1006
Changsha, Hunan, China, 410013
Actively Recruiting
20
Zai Lab Site 1008
Changchun, Jilin, China, 130012
Actively Recruiting
21
Zai Lab Site 1001
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
Research Team
Z
ZaiLab_1310-002_StudyTeam
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here